160 related articles for article (PubMed ID: 35751383)
1. Carbon tattooing of axillary lymph nodes in breast cancer patients before neoadjuvant chemotherapy: A retrospective analysis.
Porpiglia M; Borella F; Chieppa P; Brino C; Ala A; Marra V; Castellano I; Benedetto C
Tumori; 2023 Jun; 109(3):301-306. PubMed ID: 35751383
[TBL] [Abstract][Full Text] [Related]
2. Axillary Lymph Node Tattooing and Targeted Axillary Dissection in Breast Cancer Patients Who Presented as cN+ Before Neoadjuvant Chemotherapy and Became cN0 After Treatment.
Natsiopoulos I; Intzes S; Liappis T; Zarampoukas K; Zarampoukas T; Zacharopoulou V; Papazisis K
Clin Breast Cancer; 2019 Jun; 19(3):208-215. PubMed ID: 30922804
[TBL] [Abstract][Full Text] [Related]
3. Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer.
Gatek J; Petru V; Kosac P; Ratajsky M; Duben J; Dudesek B; Jancik P; Zabojnikova M; Katrusak J; Opelova P; Podrazska L; Vazan P; Kudlova P; Holik P; Melichar B; Vrana D
Neoplasma; 2020 Nov; 67(6):1329-1334. PubMed ID: 32749847
[TBL] [Abstract][Full Text] [Related]
4. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
de Boniface J; Frisell J; Kühn T; Wiklander-Bråkenhielm I; Dembrower K; Nyman P; Zouzos A; Gerber B; Reimer T; Hartmann S
Breast Cancer Res Treat; 2022 Jun; 193(3):589-595. PubMed ID: 35451733
[TBL] [Abstract][Full Text] [Related]
5. A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients.
Goyal A; Puri S; Marshall A; Valassiadou K; Hoosein MM; Carmichael AR; Erdelyi G; Sharma N; Dunn J; York J
Breast Cancer Res Treat; 2021 Jan; 185(2):433-440. PubMed ID: 33025481
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound guided tattooing of axillary lymph nodes in breast cancer patients prior to neoadjuvant therapy, and identification of tattooed nodes at the time of surgery.
Allweis TM; Menes T; Rotbart N; Rapson Y; Cernik H; Bokov I; Diment J; Magen A; Golan O; Levi-Bendet N; Givon Madhala O; Grubstein A
Eur J Surg Oncol; 2020 Jun; 46(6):1041-1045. PubMed ID: 31801656
[TBL] [Abstract][Full Text] [Related]
7. Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study.
Yang X; Li Y; Ren XT; Fan L; Hua B
World J Surg Oncol; 2023 Jul; 21(1):214. PubMed ID: 37480099
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients.
Park S; Koo JS; Kim GM; Sohn J; Kim SI; Cho YU; Park BW; Park VY; Yoon JH; Moon HJ; Kim MJ; Kim EK
Cancer Res Treat; 2018 Jul; 50(3):801-812. PubMed ID: 28814071
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
[TBL] [Abstract][Full Text] [Related]
10. Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer.
Simons JM; van Pelt MLMA; Marinelli AWKS; Straver ME; Zeillemaker AM; Pereira Arias-Bouda LM; van Nijnatten TJA; Koppert LB; Hunt KK; Smidt ML; Luiten EJT; van der Pol CC
Br J Surg; 2019 Nov; 106(12):1632-1639. PubMed ID: 31593294
[TBL] [Abstract][Full Text] [Related]
11. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.
Aragon-Sanchez S; Oliver-Perez MR; Madariaga A; Tabuenca MJ; Martinez M; Galindo A; Arroyo ML; Gallego M; Blanco M; Ciruelos-Gil EM
Breast J; 2022; 2022():1507881. PubMed ID: 36051467
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.
Song YX; Xu Z; Liang MX; Liu Z; Hou JC; Chen X; Xu D; Fei YJ; Tang JH
Cancer Med; 2022 Nov; 11(22):4085-4103. PubMed ID: 35502768
[TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation.
Takei H; Yoshida T; Kurosumi M; Inoue K; Matsumoto H; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Kubo K; Oba H; Nagai S; Tabei T
Int J Clin Oncol; 2013 Jun; 18(3):547-53. PubMed ID: 22588780
[TBL] [Abstract][Full Text] [Related]
15. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
[TBL] [Abstract][Full Text] [Related]
16. First Reported Use of Radiofrequency Identification (RFID) Technique for Targeted Excision of Suspicious Axillary Lymph Nodes in Early Stage Breast Cancer - Evaluation of Feasibility and Review of Current Recommendations.
Malter W; Eichler C; Hanstein B; Mallmann P; Holtschmidt J
In Vivo; 2020; 34(3):1207-1213. PubMed ID: 32354911
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node.
Patel R; MacKerricher W; Tsai J; Choy N; Lipson J; Ikeda D; Pal S; De Martini W; Allison KH; Wapnir IL
Ann Surg Oncol; 2019 Aug; 26(8):2452-2458. PubMed ID: 31087176
[TBL] [Abstract][Full Text] [Related]
18. Clipping a Positive Lymph Node Improves Accuracy of Nodal Staging After Neoadjuvant Chemotherapy for Breast Cancer Patients, but Does It Drive Management Changes?
Costarelli L; Arienzo F; Broglia L; La Pinta M; Scavina P; Meli EZ; Colavito MH; Ascarelli A; Campagna D; Mastropietro T; Manna E; Amato M; Andrulli AD; Schiavone A; Minelli M; Fortunato L
Ann Surg Oncol; 2024 May; 31(5):3186-3193. PubMed ID: 38427160
[TBL] [Abstract][Full Text] [Related]
19. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
[TBL] [Abstract][Full Text] [Related]
20. Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients.
Pinto CS; Peleteiro B; Pinto CA; Osório F; Costa S; Magalhães A; Mora H; Amaral J; Gonçalves D; Fougo JL
Breast Cancer; 2022 Jul; 29(4):709-719. PubMed ID: 35304711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
